Eubulus Biotherapeutics Overview
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
2ndary - Private
- Investors
-
5
Eubulus Biotherapeutics General Information
Description
Operator of a biotechnology company intended to develop innovative drugs based on targeting protein degradation technology. The company offers innovative and versatile platform technology for therapeutic enhancement, its cell-targeted enzymatic degradation drug TED platform is different from the traditional PROTAC, thereby targeting effective delivery, multi-functionality, and more safety.
Contact Information
Corporate Office
- 3rd Floor, Building B, Number 51 Wufeng Road, Xincheng Street
- Xiuzhou District
- Jiaxing, Zhejiang 900000
- China
Corporate Office
- 3rd Floor, Building B, Number 51 Wufeng Road, Xincheng Street
- Xiuzhou District
- Jiaxing, Zhejiang 900000
- China
Eubulus Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 16-Feb-2023 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 01-Mar-2022 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 12-Oct-2021 | Completed | Generating Revenue | |||
| 2. Grant | 01-Dec-2020 | $30.3K | Completed | Generating Revenue | ||
| 1. Joint Venture | 03-Apr-2018 | Completed | Generating Revenue |
Eubulus Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Eubulus Biotherapeutics Patents
Eubulus Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025180414-A1 | Cyclin modulator | Pending | 26-Feb-2024 | ||
| WO-2024041661-A1 | Cyclin modulator | Inactive | 26-Aug-2022 | ||
| WO-2023098831-A1 | Targeted protease degradation (ted) platform | Inactive | 01-Dec-2021 | ||
| US-20250041306-A1 | Targeted protease degradation (ted) platform | Pending | 09-Oct-2021 | ||
| WO-2023056981-A1 | Targeted protease degradation (ted) platform | Inactive | 09-Oct-2021 | A61K31/506 |
Eubulus Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Eubulus Biotherapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| The Innovation and Technology Commission | Government | Minority | ||
| Viva Ventures Biotech Group | Venture Capital | Minority | ||
| Changrong Capital | Venture Capital | Minority | ||
| JMCR Family Office | Family Office | Minority | ||
| Star Capital Investment Management | Growth/Expansion | Minority |
Eubulus Biotherapeutics FAQs
-
Where is Eubulus Biotherapeutics headquartered?
Eubulus Biotherapeutics is headquartered in Jiaxing, China.
-
What is the size of Eubulus Biotherapeutics?
Eubulus Biotherapeutics has 2 total employees.
-
What industry is Eubulus Biotherapeutics in?
Eubulus Biotherapeutics’s primary industry is Biotechnology.
-
Is Eubulus Biotherapeutics a private or public company?
Eubulus Biotherapeutics is a Private company.
-
What is Eubulus Biotherapeutics’s current revenue?
The current revenue for Eubulus Biotherapeutics is .
-
How much funding has Eubulus Biotherapeutics raised over time?
Eubulus Biotherapeutics has raised $9.3M.
-
Who are Eubulus Biotherapeutics’s investors?
The Innovation and Technology Commission, Viva Ventures Biotech Group, Changrong Capital, JMCR Family Office, and Star Capital Investment Management have invested in Eubulus Biotherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
